Renal Denervation: A Review of Current Devices, Techniques, and Evidence.

Hypertension is a major contributor to morbidity and mortality in the United States, and its management remains a significant challenge for clinicians. Transcatheter renal denervation targeting sympathetic nervous system overactivity offers an additive benefit to medications for patients with uncontrolled hypertension as well as for patients who are not able or unwilling to be treated with medications. Two devices were recently approved for commercial use that employ radiofrequency ablative and ultrasound energy for renal denervation. Both devices have shown durable treatment effects up to 3 years with minimal device-related safety concerns.